Skip to main
GILD
GILD logo

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 30%
Buy 45%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences demonstrates a positive outlook driven by robust sales growth, particularly highlighted by Biktarvy capturing 52% of the U.S. market share, reflecting an increase from 49% in the previous quarter. The company's proactive approach in the HIV market, along with rising awareness and education around PrEP, has led to an increased sales forecast, revising growth guidance to 5% year-over-year despite anticipated Medicare Part D challenges. Additionally, the strong performance of Livdelzi, which recorded $105 million in sales and a notable 35% quarter-over-quarter growth in its first full year, underscores the potential for continued success across Gilead's therapeutic portfolio.

Bears say

Gilead Sciences is experiencing significant revenue decline across multiple therapeutic areas, with notable drops in both Trodelvy and Veklury sales, indicating challenges in maintaining market share against competitors. The company has forecasted a roughly 10% decrease in cell therapy revenue for FY2025, reflecting ongoing competitive pressures that are anticipated to persist in the oncology market. Additionally, Veklury revenue is projected to fall to $1.0 billion for FY2025, a substantial reduction from previous guidance, further emphasizing the company's struggles in a declining demand environment.

Gilead Sciences (GILD) has been analyzed by 20 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 45% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 20 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Nov 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.